Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 11 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				40 to 90				Pharmaceutical / Industry				AVO108943 NCT00470834


2.		Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care, Treatment				Approved-not yet active				35 to 90				Other, Pharmaceutical / Industry				047838 NCT00805701


3.		Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablation Therapy for Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				45 to 80				Other				CURC/CUOG-AVIAS-0601 NCT00553878


4.		Study of Tamsulosin and/or Dutasteride to Relieve Urinary Symptoms After Brachytherapy for Localized Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Active				18 and over				Other				CCF IRB 8019 GSK106046 (formerly 103988), NCT00244309

Last Modified: 6/9/2008 First Published: 11/3/2006


5.		Phase III Randomized Study of Dutasteride Followed By Contrast-Enhanced, Ultrasound-Guided Targeted Biopsy for the Detection of Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Diagnostic				Active				18 to 80				NCI				TJUH-06F-145 NCT00398281


6.		Prevention of Prostate Cancer With Dutasteride in Case of High Grade PIN Neoplasia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Prevention				Active				40 to 80				Other				BE-2-27 NCT00780754


7.		Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				05-8538-V 01 FHCRC-05026, NCT00298155

Last Modified: 1/13/2009 First Published: 8/10/2007


8.		Phase II Randomized Study of Dutasteride and Intermittent Androgen-Ablation Therapy in Patients Who Have Undergone Prior Radiotherapy and/or Surgery for Localized Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				45 to 80				NCI				FHCRC-6408 6408, UWCC-UW 6408, UWCC- 06-4211-H/B, NCT00516815


9.		ARTS - AVODART After Radical Therapy For Prostate Cancer Study

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 to 85				Pharmaceutical / Industry				ARI109924 NCT00558363


10.		Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Other				EH07-109 NCT00668642

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute